OTCMKTS:AGYTF Allergy Therapeutics (AGYTF) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free AGYTF Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.02▼$0.0250-Day Range N/A52-Week Range$0.17▼$0.19VolumeN/AAverage Volume844 shsMarket Capitalization$13.78 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisHeadlinesShort InterestStock AnalysisHeadlinesShort Interest Get Allergy Therapeutics alerts: Email Address Ad Insiders ExposedThis consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here. About Allergy Therapeutics Stock (OTCMKTS:AGYTF)Allergy Therapeutics plc engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Acarovac MPL, Venomil, Synbiotics, Penicillin Diagnostics, and Peanut. The company also develops allergy vaccines for grass, tree, and house dust mite, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.Read More Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. AGYTF Stock News HeadlinesMarch 26, 2024 | finance.yahoo.comHAPPY HOPPY HOLIDAY AT GALAXY MACAU WITH EGGS-TRA SPECIAL EASTER MENUSMarch 20, 2024 | msn.comNokian Outpost AT long-term wrap-up: Decent tires, snow or noMarch 29, 2024 | WealthPress (Ad)A lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. March 19, 2024 | finance.yahoo.comREDCON1 ENERGY LAUNCHES AT CIRCLE K STORESMarch 15, 2024 | msn.comMONDAY AT 6: KATU exclusive report reveals plead deal trends in Mult. Co. murder casesMarch 13, 2024 | msn.comTOMORROW AT 6| KATU will hold a town hall on the future of Portland's fentanyl crisisMarch 12, 2024 | msn.comAllergy Therapeutics doses patients in second part of peanut allergy trialMarch 12, 2024 | finance.yahoo.comYALO RISES HIGH AT THE HORIZON AWARDS WITH MULTIPLE WINSMarch 29, 2024 | Crypto 101 Media (Ad)Crypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.March 12, 2024 | lse.co.ukAllergy Therapeutics starts dosing patients in peanut allergy trialMarch 8, 2024 | msn.comSOME REPUBLICANS THINK BIDEN DID TOO MUCH YELLING AT SOTUFebruary 29, 2024 | finance.yahoo.comWebinar: AT&S introduces the future of computingFebruary 27, 2024 | finance.yahoo.comJESSICA EGERTON, A SEASONED MARKETING EXECUTIVE WITH TWO DECADES OF BUILDING BRANDS, NAMED VICE PRESIDENT OF MARKETING AT KUMHO TIRE U.S.A.February 23, 2024 | msn.comAT LAST! Urban Boarding Experience plans big expansionFebruary 22, 2024 | markets.businessinsider.comIntrommune Therapeutics Presents Supporting Data Introducing a New Form of Food Allergy TreatmentFebruary 21, 2024 | msn.comLEGO's AT-AT set gets a big price cutFebruary 20, 2024 | msn.comYokohama launches Geolandar X-AT and M/T G003 tyres in IndiaFebruary 19, 2024 | msn.comAT THE PLATE: See Jacksonville high school softball top teams, players to watch in 2024February 17, 2024 | news.yahoo.comScammers using new, hard to see device to steal your information from ATMsFebruary 16, 2024 | msn.comTODAY AT 530: Scammers using new, hard to see device to steal your information from ATMsFebruary 13, 2024 | msn.comAT, KiwiRail, Auckland One Rail in for ‘bloody good bollocking’ from Wayne BrownFebruary 12, 2024 | msn.com'Aucklanders deserve better': AT demands better network after train cancellations due to 'heat' on a 'mildly warm' dayFebruary 8, 2024 | msn.comAT names 14 runners for Ghana’s All Africa GamesFebruary 5, 2024 | finance.yahoo.comSPRING BREAK AT ESPACE POUR LA VIE: A BIO-DIVERSITY OF ACTIVITIESFebruary 5, 2024 | finance.yahoo.comHIGHWOOD ASSET MANAGEMENT LTD. PROVIDES OPERATIONAL UPDATE, INCLUDING 1,000 BBL/DAY LIGHT OIL WELL AT WILSON CREEK AND REITERATES 2024 GUIDANCEFebruary 2, 2024 | markets.businessinsider.comEQS-News: AT&S prepares for the upcoming market recovery despite a challenging environmentJanuary 31, 2024 | finance.yahoo.comGREATER DES MOINES PARTNERSHIP ANNOUNCES 2024 STRATEGIC PRIORITIES AT ANNUAL DINNERSee More Headlines Receive AGYTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allergy Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/28/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryN/A Current SymbolOTCMKTS:AGYTF Previous SymbolNASDAQ:AGYTF CUSIPN/A CIKN/A Webwww.allergytherapeutics.com Phone44-19-0384-4700FaxN/AEmployees600Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.80 Quick Ratio1.19 Sales & Book Value Annual Sales$73.41 million Price / Sales0.19 Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / Book-2.00Miscellaneous Outstanding Shares688,950,000Free FloatN/AMarket Cap$13.78 million OptionableNot Optionable Beta519.17 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Manuel Llobet (Age 57)CEO & Exec. Director Comp: $683.78kMr. Nicolas Alexander Ulrich Wykeman (Age 56)CFO & Exec. Director Comp: $392.3kMs. Beverly LeesGroup Operations DirectorDr. Murray SkinnerChief Scientific OfficerMr. Santiago PuigBus. Devel. DirectorMs. Sue BakerHead of HRSimon PiggottHead of Clinical ScienceAlan BullimoreHead of Communication & Market Devel.Mr. Russell PicketGroup Financial ControllerSara GoldsbroughCompany Sec.More ExecutivesKey CompetitorsPoxelOTCMKTS:PXXLFPreveCeutical MedicalOTCMKTS:PRVCFBZAMOTCMKTS:BZAMFNicoxOTCMKTS:NICXFMDxHealthOTCMKTS:MXDHFView All Competitors This page (OTCMKTS:AGYTF) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allergy Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.